JPMorgan Chase & Co. Increases Replimune Group (NASDAQ:REPL) Price Target to $18.00

Replimune Group (NASDAQ:REPL) had its price objective boosted by equities research analysts at JPMorgan Chase & Co. from $16.00 to $18.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 32.77% from the company’s current price.

REPL has been the topic of a number of other reports. Jefferies Financial Group raised their price objective on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. HC Wainwright boosted their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Finally, BMO Capital Markets increased their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $19.43.

Replimune Group Stock Up 0.5 %

Shares of NASDAQ:REPL traded up $0.07 during trading hours on Wednesday, reaching $13.56. The stock had a trading volume of 135,685 shares, compared to its average volume of 718,737. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. Replimune Group has a 1 year low of $4.92 and a 1 year high of $17.00. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -4.43 and a beta of 1.30. The firm’s 50 day moving average is $12.74 and its 200-day moving average is $11.95.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). Research analysts predict that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Hedge funds and other institutional investors have recently made changes to their positions in the business. Baker BROS. Advisors LP increased its stake in Replimune Group by 10.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after buying an additional 1,000,000 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Replimune Group by 11.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company’s stock valued at $132,761,000 after buying an additional 1,083,633 shares in the last quarter. Redmile Group LLC grew its stake in shares of Replimune Group by 2.6% in the 4th quarter. Redmile Group LLC now owns 4,905,527 shares of the company’s stock worth $59,406,000 after purchasing an additional 124,344 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Replimune Group by 3.7% during the 4th quarter. Vanguard Group Inc. now owns 3,595,848 shares of the company’s stock valued at $43,546,000 after acquiring an additional 129,601 shares during the last quarter. Finally, Braidwell LP boosted its stake in shares of Replimune Group by 203.0% during the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after acquiring an additional 2,057,460 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.